Early career · publishing since 2019Rising activity
Colorectal Cancer Treatments and StudiesPancreatic and Hepatic Oncology ResearchBiochemical and Molecular ResearchLung Cancer Treatments and MutationsAdvanced Breast Cancer Therapies
Publications
26
Citations
56
Est. group size
—
Recurring co-author estimate
Active years
6
Publishing since 2019
In context
Among 1,353 early career Medicine PIs within our index
Citations: 56p25 74 · p75 317 · cohort median 157
Publications / year (recent): 4.2p25 1.8 · p75 4.4 · cohort median 2.6
Typically publishes in teams of ~20 · 0% small-team papers (≤3 authors) · across 3 venues
Publication cadence
Publications per year over the last 10 years — averaging 4.2/year recently
Collaborators per year
Distinct co-authors at University of Michigan each year — a rough indication of whether the group around this researcher has been growing or contracting. An estimate from co-authorship, not a roster: collaborators are not necessarily lab members, and recent years can be under-counted while indexing catches up.
Recent publications
- Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i> G12C-Mutant Pancreatic and Lung Cancers
Molecular Cancer Therapeutics · 2023
- Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers
bioRxiv (Cold Spring Harbor Laboratory) · 2023
- Supplementary Fig S1 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
2023
- Supplementary Fig S1 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
2023
- Supplementary Table S1 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
2023
- Supplementary Fig S2 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
2023
- Supplementary Fig S5 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
2023
- Supplementary Fig S6 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
2023
- Supplementary Fig S3 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
2023
- Data from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
2023
- Data from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
2023
- Supplementary Fig S3 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
2023
- Supplementary Fig S4 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
2023
- Supplementary Fig S4 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
2023
- Supplementary Fig S6 from Anticancer Efficacy of KRAS<sup>G12C</sup> Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of <i>KRAS</i><sup>G12C</sup>-Mutant Pancreatic and Lung Cancers
2023
Publishes in
- Elsevier eBooks×2
- Cancer Research×2
- Scientific Reports×1
- Molecular Cancer Therapeutics×1
- The Laryngoscope×1
Similar researchers
By research-topic overlap
- Bert H. O’Neil
Medicine · Indiana University
- Mingjia Li
Medicine · The Ohio State University
- J. Kevin Hicks
Medicine · University of Michigan
- Eric D. Miller
Medicine · The Ohio State University
- Wei Chen
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile